嘉誠國際(603535.SH):2021年半年報及其摘要披露日期變更為8月28日
格隆匯8月17日丨嘉誠國際(603535.SH)公佈,公司原計劃於2021年8月20日在中國證監會指定的信息披露媒體上披露《公司2021年半年度報吿》及其摘要。由於公司編制定期報吿的同時正在推進非公開發行公司股票事項,定期報吿預計完成時間晚於預期,為確保公司信息披露的完整性和準確性,經公司研究決定,並向上海證券交易所申請,《公司2021年半年度報吿》及其摘要披露日期由2021年8月20日變更為2021年8月28日。
公司董事會對本次調整半年度報吿披露時間給投資者帶來的不便致以誠摯的歉意,敬請廣大投資者諒解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.